Neuromuscular Disorders
Volume 17, Issue 5 , Pages 423-428 , May 2007

145th ENMC International Workshop: Planning for an International Trial of Steroid Dosage Regimes in DMD (FOR DMD) 22–24th October 2006, Naarden, The Netherlands

  • K. Bushby

      Affiliations

    • Institute of Human Genetics, International Centre for Life, Central Parkway, Newcastle upon Tyne NE1 3BZ, UK
    • Corresponding Author InformationCorresponding author. Tel.: +44 191 241 8737; fax: +44 191 241 8799.
    • ,
  • R. Griggs

      Affiliations

    • University of Rochester Medical Center, New York, NY 14642, USA
    • ,
  • on behalf of the MSG/ENMC FOR DMD trial study group

Received 20 December 2006

References 

  1. Bushby K, Muntoni F, et al. (2004). Report on the 124th ENMC International Workshop. Treatment of Duchenne muscular dystrophy; defining the gold standards of management in the uses of corticosteroids. 2–4 April 2004, Naarden, The Netherlands. Neuromusc Disord 14(8–9):526–34.
  2. Manzur AY, Kuntzer T, et al. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev. 2004;(2):CD003725
  3. Moxley RT, Ashwal S, et al. Corticosteroid treatment of Duchenne dystrophy [Report of the Quality standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society]. Neurology. 2005;64(1):13–20
  4. Silversides CK, Webb GD, et al. Effects of deflazacort on left ventricular function in patients with Duchenne muscular dystrophy. Am J Cardiol. 2003;91(6):769–772
  5. Biggar WD, Politano L, et al. Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols. Neuromuscul Disord. 2004;14(8-9):476–482
  6. Biggar WD, Harris VA, et al. Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscul Disord. 2006;16(4):249–255
  7. Braun S. Naked plasmid DNA for the treatment of muscular dystrophy. Curr Opin Mol Ther. 2004;6(5):499–505
  8. Goyenvalle A, Vulin A, et al. Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping. Science. 2004;306(5702):1796–1799
  9. Nelson R. Utrophin therapy for Duchenne muscular dystrophy?. Lancet Neurol. 2004;3(11):637
  10. Romero NB, Braun S, et al. Phase I study of dystrophin plasmid-based gene therapy in Duchenne/Becker muscular dystrophy. Hum Gene Ther. 2004;15(11):1065–1076
  11. Fardeau M, Braun S, et al. [About a phase I gene therapy clinical trial with a full-length dystrophin gene-plasmid in Duchenne/Becker muscular dystrophy]. J Soc Biol. 2005;199(1):29–32
  12. Hirst RC, McCullagh KJ, et al. Utrophin upregulation in Duchenne muscular dystrophy. Acta Myol. 2005;24(3):209–216
  13. Liu M, Yue Y, et al. Adeno-associated virus-mediated microdystrophin expression protects young mdx muscle from contraction-induced injury. Mol Ther. 2005;11(2):245–256
  14. Alter J, Lou F, et al. Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat Med. 2006;12(2):175–177
  15. Beroud C, Tuffery-Giraud S, et al. Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy. Hum Mutat. 2006;
  16. Fletcher S, Honeyman K, et al. Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligonucleotide. J Gene Med. 2006;8(2):207–216
  17. Gregorevic P, Allen JM, et al. rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice. Nat Med. 2006;12(7):787–789
  18. Hamed SA. Drug evaluation: PTC-124 – a potential treatment of cystic fibrosis and Duchenne muscular dystrophy. IDrugs. 2006;9(11):783–789
  19. Miura P, Jasmin BJ. Utrophin upregulation for treating Duchenne or Becker muscular dystrophy: how close are we?. Trends Mol Med. 2006;12(3):122–129
  20. Sampaolesi M, Blot S, et al. Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs. Nature. 2006;
  21. Wilton SD, Fletcher S. Redirecting splicing to address dystrophin mutations: molecular by-pass surgery. Prog Mol Subcell Biol. 2006;44:161–197
  22. Bogdanovich S, Krag TO, et al. Functional improvement of dystrophic muscle by myostatin blockade. Nature. 2002;420(6914):418–421
  23. Bogdanovich S, Perkins KJ, et al. Myostatin propeptide-mediated amelioration of dystrophic pathophysiology. FASEB J. 2005;19(6):543–549
  24. Whittemore LA, Song K, et al. Inhibition of myostatin in adult mice increases skeletal muscle mass and strength. Biochem Biophys Res Commun. 2003;300(4):965–971
  25. Atkinson MJ, Sinah A, et al. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Quality Life Outcomes. 2004;2(12):
  26. Scott E, Mawson SJ. Measurement in Duchenne muscular dystrophy: considerations in the development of a neuromuscular assessment tool. Dev Med Child Neurol. 2006;48(6):540–544
  27. Bianchi ML, Mazzanti A, et al. Bone mineral density in Duchenne muscular dystrophy. Osteoporosis Int. 2003;14:761–767
  28. Biggar LK, Bachrach RC, et al. (2005). Bone health in Duchenne muscular dystrophy: a workshop report from the meeting in Cincinnati, Ohio, July 8, 2004. Neuromuscul Disord 15(1):80–5.
  29. Quinlivan R, Roper H, et al. Report of a Muscular Dystrophy Campaign funded workshop Birmingham, UK, January 16th 2004. Osteoporosis in Duchenne muscular dystrophy; its prevalence, treatment and prevention. [see comment]. Neuromuscul Disord. 2005;15(1):72–79
  30. Bushby KMD, Muntoni F, et al. (2003). The management of cardiac complications in muscular dystrophy and myotonic dystrophy. In: Proceedings of 107th ENMC Workshop, Neuromuscul Disord, vol. 13. p. 166–172.
  31. Finder JD, Birnkrant D, et al. Respiratory care of the patient with Duchenne muscular dystrophy: ATS consensus statement. Am J Respir Crit Care Med. 2004;170(4):456–465

PII: S0960-8966(07)00012-0

doi: 10.1016/j.nmd.2007.01.006

Neuromuscular Disorders
Volume 17, Issue 5 , Pages 423-428 , May 2007

Article Tools